Ocrevus, rituximab may not slow disability progression in PPMS

[DIM]

Anti-CD20 therapies like Ocrevus (ocrelizumab) and rituximab appear to be ineffective at slowing disability progression in people with primary progressive multiple sclerosis (PPMS), a form of the disease characterized by symptoms that steadily worsen over time, according to data from a real-world study in France.

https://multiplesclerosisnewstoday.com/ ... sion-ppms/

[David1949]

I have a friend who has PPMS. He tried Ocrevus. He is now at EDSS 9, meaning he is bed ridden and almost completely helpless. On top of that it cost him $70,000! I also have PPMS, (EDSS 6.5 or 7) but I think I'll pass on Ocrevus.

[NHE]

I have a friend who has PPMS. He tried Ocrevus. He is now at EDSS 9, meaning he is bed ridden and almost completely helpless. On top of that it cost him $70,000! I also have PPMS, (EDSS 6.5 or 7) but I think I'll pass on Ocrevus.

The following data plot is from Ocrevus' Prescribing Information. It depicts a comparison of Ocrevus vs. placebo in PPMS. It's immediately apparent that the two data plots are nearly parallel. Moreover, Ocrevus claims a 24% relative reduction between the Ocrevus and placebo treatment groups. However, an analysis of the data plot reveals that there was just a 16.8% relative reduction.